Lantheus Holdings Inc (NASDAQ:LNTH) – Investment analysts at Jefferies Group dropped their Q2 2018 earnings per share (EPS) estimates for Lantheus in a research note issued to investors on Tuesday. Jefferies Group analyst R. Denhoy now forecasts that the medical equipment provider will post earnings per share of $0.32 for the quarter, down from their prior estimate of $0.40. Jefferies Group currently has a “Buy” rating and a $27.00 price objective on the stock. Jefferies Group also issued estimates for Lantheus’ Q3 2018 earnings at $0.27 EPS and Q4 2018 earnings at $0.27 EPS.
Lantheus (NASDAQ:LNTH) last posted its earnings results on Monday, February 26th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.08). The business had revenue of $81.24 million for the quarter, compared to analyst estimates of $78.57 million. Lantheus had a net margin of 37.23% and a negative return on equity of 46.62%. The company’s revenue for the quarter was up 9.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.18 earnings per share.
Lantheus (NASDAQ:LNTH) opened at $15.35 on Wednesday. The stock has a market cap of $750.12, a price-to-earnings ratio of 4.87, a P/E/G ratio of 1.30 and a beta of 0.95. Lantheus has a 1 year low of $10.65 and a 1 year high of $24.45. The company has a current ratio of 2.96, a quick ratio of 2.46 and a debt-to-equity ratio of -3.41.
In other Lantheus news, CFO John W. Crowley sold 3,866 shares of the company’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $23.52, for a total value of $90,928.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Michael P. Duffy sold 21,655 shares of the company’s stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $22.40, for a total transaction of $485,072.00. Following the completion of the transaction, the insider now owns 156,784 shares of the company’s stock, valued at approximately $3,511,961.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 29,217 shares of company stock valued at $648,368. Insiders own 2.30% of the company’s stock.
Institutional investors have recently modified their holdings of the business. Schwab Charles Investment Management Inc. acquired a new position in shares of Lantheus in the second quarter worth about $770,000. Vanguard Group Inc. raised its position in shares of Lantheus by 87.5% in the second quarter. Vanguard Group Inc. now owns 1,478,350 shares of the medical equipment provider’s stock worth $26,093,000 after acquiring an additional 689,954 shares during the period. BNP Paribas Arbitrage SA raised its position in shares of Lantheus by 75.7% in the third quarter. BNP Paribas Arbitrage SA now owns 14,565 shares of the medical equipment provider’s stock worth $259,000 after acquiring an additional 6,274 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of Lantheus by 547.8% in the second quarter. The Manufacturers Life Insurance Company now owns 23,761 shares of the medical equipment provider’s stock worth $419,000 after acquiring an additional 20,093 shares during the period. Finally, Wells Fargo & Company MN increased its stake in shares of Lantheus by 151.9% during the third quarter. Wells Fargo & Company MN now owns 138,994 shares of the medical equipment provider’s stock worth $2,474,000 after purchasing an additional 83,821 shares in the last quarter. Institutional investors and hedge funds own 91.60% of the company’s stock.
WARNING: This news story was originally published by Ticker Report and is owned by of Ticker Report. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3227782/jefferies-group-comments-on-lantheus-holdings-incs-q2-2018-earnings-lnth.html.
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.